Pathological but not physiological retinal neovascularization is altered in TNF-Rp55-receptor-deficient mice

Investigative Ophthalmology and Visual Science

Volumn 47, Issue 11, 2006, Pages 5057-5065

  Kociok, Norbert ^a,b   Radetzky, Sven ^a   Krohne, Tim U ^a   Gavranic, Claudia ^a   Joussen, Antonia M ^a,b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; CONCANAVALIN A; OXYGEN; PLATELET DERIVED GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR P55; TUMOR NECROSIS FACTOR ALPHA RECEPTOR P75; UNCLASSIFIED DRUG; VASCULOTROPIN; AGPT PROTEIN, RAT; DRUG DERIVATIVE; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR B; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR BINDING PROTEIN 1; RECOMBINANT HUMAN TUMOR NECROSIS FACTOR-BINDING PROTEIN-1; TUMOR NECROSIS FACTOR DECOY RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; ENDOTHELIUM CELL; GENE EXPRESSION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA BLOOD VESSEL; RETINA DEVELOPMENT; RETINA NEOVASCULARIZATION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; FLUORESCENCE MICROSCOPY; GENE SILENCING; GENETICS; HUMAN; HYPEROXIA; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; RETROLENTAL FIBROPLASIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANGIOPOIETIN-1; ANIMALS; DISEASE MODELS, ANIMAL; GENE SILENCING; HUMANS; HYPEROXIA; INFANT, NEWBORN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; OXYGEN; PROTO-ONCOGENE PROTEINS C-SIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR DECOY RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34247169524     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-0407     Document Type: Article

References (53)

1. Fajardo LF, Kwan HH, Kowalski J, Prionas SD. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol. 1992;140:539-544.
2. Spranger J, Meyer-Schwickerath R, Klein M, Schatz H. [TNF-alpha level in the vitreous body. Increase in neovascular eye diseases and proliferative diabetic retinopathy]. Med Klin (Munich). 1995;90:134-137.
3. Armstrong D, Ueda T, Ueda T, Aljada A. Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor and platelet-derived growth factor. Angiogenesis. 1998;2:93-104.
4. Wallach D, Varfolomeev EE, Malinin NL, Goltsev YV. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu Rev Immunol. 1999;17:331-367.
5. Majka S, McGuire PG, Das A. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization. Invest Ophthalmol Vis Sci. 2002;43:260-266.
6. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002;16:438-440.
7. Cohen PS, Nakshatri H, Dennis J, Caragine T. CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Proc Natl Acad Sci USA. 1996;93:3967-3971.
8. Bianchi M, Bloom O, Raabe T, Cohen PS. Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. J Exp Med. 1996;183:927-936.
9. Gardiner TA, Gibson DS, de Gooyer TE, de La Cruz V, McDonald DM, Stitt, AW. Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am J Pathol. 2005;166:637-644.
10. Smith LE, Wesolowski E, McLellan A, Kostyk SK. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
11. Alon T, Hemo I, Itin A, Pe'er J. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1:1024-1028.
12. Stone J, Itin A, Alon T, Pe'er J. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995;15:4738-4747.
13. Brooks SE, Gu X, Samuel S, Marcus DM. Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice. Invest Ophthalmol Vis Sci. 2001;42:222-228.
14. Simpson DA, Murphy GM, Bhaduri T, Gardiner TA. Expression of the VEGF gene family during retinal vaso-obliteration and hypoxia. Biochem Biophys Res Commun. 1999;262:333-340.
15. Pierce EA, Avery RL, Foley ED, Aiello LP. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA. 1995;92:905-909.
16. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development. 1998;125:1591-1598.
17. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-dencient mice. Science. 1997;277:242-245.
18. Maisonpierre PC, Suri C, Jones PF, Bartunkova S. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55-60.
19. Davis S, Aldrich TH, Jones PF, Acheson A. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996;87:1161-1169.
20. Asahara T, Chen D, Takahashi T, Fujikawa K. Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. Circ Res. 1998;83:233-240.
21. Ishida S, Yamashiro K, Usui T, Kaji Y. Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med. 2003;9:781-788.
22. Morrison TB, Weis JJ, Wittwer CT. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. BioTechniques. 1998;24:954-958,960,962.
23. Vandesompele J, De Preter K, Pattyn F, Poppe B. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3:RESEARCH0034.
24. Ilg RC, Davies MH, Powers MR. Altered retinal neovascularization in TNF receptor-deficient mice. Curr Eye Res. 2005;30:1003-1013.
25. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:671-674.
26. Frater-Schroder M, Risau W, Hallmann R, Gautschi P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc Natl Acad Sci USA. 1987;84:5277-5281.
27. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha. Nature. 1987;329:630-632.
28. Ryuto M, Ono M, Izumi H, Yoshida S. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells: possible roles of SP-1. J Biol Chem. 1996;271:28220-28228.
29. Battegay EJ, Raines EW, Colbert T, Ross R. TNF-alpha stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression. J Immunol. 1995;154:6040-6047.
30. Koblizek TI, Weiss C, Yancopoulos GD, Deutsch U. Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol. 1998;8:529-532.
31. Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD. Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem. 1998;273:18514-18521.
32. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest. 1999;79:213-223.
33. Suri C, Jones PF, Patan S, Bartunkova S. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87:1171-1180.
34. Vikkula M, Boon LM, Carraway KL, III, Calvert JT. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell. 1996;87:1181-1190.
35. Gamble JR, Drew J, Trezise L, Underwood A. Angiopoietin-1 Is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions. Circ Res. 2000;87:603-607.
36. Thurston G, Rudge JS, Ioffe E, Zhou H. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med. 2000;6:460-463.
37. Joussen AM, Poulaki V, Tsujikawa A, Qin W. Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol. 2002;160:1683-1693.
38. Lemieux C, Maliba R, Favier J, Theoret JF. Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses. Blood. 2005;105:1523-1530.
39. Oh H, Takagi H, Suzuma K, Otani A. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem. 1999;274:15732-15739.
40. Willam C, Koehne P, Jurgensen JS, Grafe M. Tie2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells. Circ Res. 2000;87:370-377.
41. Enholm B, Paavonen K, Ristimaki A, Kumar V. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene. 1997;14:2475-2483.
42. Scott BB, Zaratin PF, Colombo A, Hansbury MJ. Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. J Rheumatol. 2002;29:230-239.
43. Hangai M, He S, Hoffmann S, Lim JI. Sequential induction of angiogenic growth factors by TNF-alpha in choroidal endothelial cells. J Neuroimmunol. 2006;171:45-56.
44. Sarlos S, Rizkalla B, Moravski CJ, Cao Z. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol. 2003;163:879-887.
45. Hackett SF, Ozaki H, Strauss RW, Wahlin K. Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization. J Cell Physiol. 2000;184:275-284.
46. Mandriota SJ, Pepper MS. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res. 1998;83:852-859.
47. Otani A, Takagi H, Oh H, Koyama S. Angiotensin II induces expression of the Tie2 receptor ligand, angiopoietin-2, in bovine retinal endothelial cells. Diabetes. 2001;50:867-875.
48. Zhang L, Yang N, Park JW, Katsaros D. Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res. 2003;63:3403-3412.
49. Pichiule P, Chavez JC, LaManna JC. Hypoxic regulation of angiopoietin-2 expression in endothelial cells. J Biol Chem. 2004;279:12171-12180.
50. Kim I, Kim JH, Ryu YS, Liu M. Tumor necrosis factor-[alpha] upregulates angiopoietin-2 in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2000;269:361-365.
51. Hackett SF, Wiegand S, Yancopoulos G, Campochiaro PA. Angiopoietin-2 plays an important role in retinal angiogenesis. J Cell Physiol. 2002;192:182-187.
52. Abdulmalek K, Ashur F, Ezer N, Ye F. Differential expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats. Am J Physiol. 2001;281:L582-L590.
53. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999;401:86-90.